In the past week, ERAS stock has gone up by 5.07%, with a monthly gain of 1.75% and a quarterly surge of 20.33%. The volatility ratio for the week is 9.77%, and the volatility levels for the last 30 days are 9.29% for Erasca Inc. The simple moving average for the past 20 days is 0.42% for ERAS’s stock, with a -27.06% simple moving average for the past 200 days.
Is It Worth Investing in Erasca Inc (NASDAQ: ERAS) Right Now?
The 36-month beta value for ERAS is also noteworthy at 1.05. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ERAS is 160.60M, and at present, short sellers hold a 13.05% of that float. The average trading volume of ERAS on July 02, 2025 was 1.59M shares.
ERAS) stock’s latest price update
Erasca Inc (NASDAQ: ERAS)’s stock price has gone rise by 6.62% in comparison to its previous close of $1.36, however, the company has experienced a 5.07% increase in its stock price over the last five trading days. globenewswire.com reported 2025-06-02 that Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor, for the treatment of patients with KRAS-mutant (KRASm) solid tumors. “Our RAS-targeting franchise continues to meaningfully advance, and now with clearance of our IND for ERAS-4001, we are excited to advance both ERAS-4001 and ERAS-0015 into the clinic ahead of our guidance,” said Jonathan E.
Analysts’ Opinion of ERAS
Many brokerage firms have already submitted their reports for ERAS stocks, with Raymond James repeating the rating for ERAS by listing it as a “Outperform.” The predicted price for ERAS in the upcoming period, according to Raymond James is $5 based on the research report published on March 26, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see ERAS reach a price target of $6. The rating they have provided for ERAS stocks is “Buy” according to the report published on November 18th, 2024.
CapitalOne gave a rating of “Overweight” to ERAS, setting the target price at $8 in the report published on March 11th of the previous year.
ERAS Trading at 4.86% from the 50-Day Moving Average
After a stumble in the market that brought ERAS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.97% of loss for the given period.
Stock Fundamentals for ERAS
The total capital return value is set at -0.35. Equity return is now at value -45.82, with -37.47 for asset returns.
Based on Erasca Inc (ERAS), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -2.12.
Currently, EBITDA for the company is -157.84 million with net debt to EBITDA at 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.35.
Conclusion
In summary, Erasca Inc (ERAS) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
